Clinical trial
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release…
NCT01197378 · Amgen, Industry · Completed
Key facts
| NCT number | NCT01197378 |
|---|---|
| Title | Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) |
| Official title | A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cystinosis |
| Intervention type | Drug |
| Interventions | Cysteamine Bitartrate Delayed-release Capsules |
| Enrollment | 60 |
| Start date | Aug 27, 2010 |
| Primary completion | Jun 26, 2017 |
| Completion | Jun 26, 2017 |
| First posted | Sep 9, 2010 |
| Last update posted | Dec 27, 2024 |
| Countries | France, Netherlands, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: